A Survey of the Regulatory Requirements for the Waiver of In Vivo Bioequivalence Studies of Generic Products in Certain Dosage Forms by Participating Regulators and Organisations of the International Pharmaceutical Regulators Programme
The requirements to waive in vivo bioequivalence studies for immediate release solid oral dosage forms based on the Biopharmaceutics Classifications System (BCS) are well known, and biowaivers[1] for other types of oral dosage forms based on pre-defined criteria may also be acceptable. Similarly, bi...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2021-03-01
|
| シリーズ: | Journal of Pharmacy & Pharmaceutical Sciences |
| オンライン・アクセス: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31491 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|
